- Home
- MRBK vs SLS Comparison
MRBK vs SLS Comparison
Compare MRBK & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRBK
- SLS
- Stock Information
- Founded
- MRBK 2004
- SLS 2012
- Country
- MRBK United States
- SLS United States
- Employees
- MRBK N/A
- SLS N/A
- Industry
- MRBK Major Banks
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- MRBK Finance
- SLS Health Care
- Exchange
- MRBK Nasdaq
- SLS Nasdaq
- Market Cap
- MRBK 145.8M
- SLS 169.6M
- IPO Year
- MRBK 2017
- SLS N/A
- Fundamental
- Price
- MRBK $12.95
- SLS $2.14
- Analyst Decision
- MRBK Buy
- SLS
- Analyst Count
- MRBK 2
- SLS 0
- Target Price
- MRBK $17.00
- SLS N/A
- AVG Volume (30 Days)
- MRBK 99.2K
- SLS 3.4M
- Earning Date
- MRBK 07-25-2025
- SLS 08-12-2025
- Dividend Yield
- MRBK 4.02%
- SLS N/A
- EPS Growth
- MRBK 33.85
- SLS N/A
- EPS
- MRBK 1.42
- SLS N/A
- Revenue
- MRBK $101,096,000.00
- SLS N/A
- Revenue This Year
- MRBK $20.44
- SLS N/A
- Revenue Next Year
- MRBK $10.56
- SLS N/A
- P/E Ratio
- MRBK $8.79
- SLS N/A
- Revenue Growth
- MRBK 8.82
- SLS N/A
- 52 Week Low
- MRBK $10.04
- SLS $0.77
- 52 Week High
- MRBK $17.33
- SLS $2.22
- Technical
- Relative Strength Index (RSI)
- MRBK 46.78
- SLS 58.92
- Support Level
- MRBK $11.16
- SLS $1.50
- Resistance Level
- MRBK $13.00
- SLS $2.04
- Average True Range (ATR)
- MRBK 0.51
- SLS 0.13
- MACD
- MRBK 0.01
- SLS 0.03
- Stochastic Oscillator
- MRBK 57.85
- SLS 69.30
About MRBK Meridian Corporation
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.